Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 14;229(3):775-779.
doi: 10.1093/infdis/jiad433.

Hepatitis C Treatment in People With HIV: Potential to Eliminate Disease and Disparity

Oluwaseun Falade-Nwulia  1 , Catherine R Lesko  2 , Anthony T Fojo  3 , Jeanne C Keruly  1 , Richard D Moore  3 , Catherine G Sutcliffe  2 , Shruti H Mehta  2 , Geetanjali Chander  4 , David L Thomas  1 , Mark Sulkowski  1
Affiliations

Hepatitis C Treatment in People With HIV: Potential to Eliminate Disease and Disparity

Oluwaseun Falade-Nwulia et al. J Infect Dis. .

Abstract

Access to direct acting antivirals (DAAs) may be associated with reductions in hepatitis C virus (HCV) viremia prevalence among people with human immunodeficiency virus (PWH). Among 3755 PWH, estimated HCV viremia prevalence decreased by 94.0% from 36% (95% confidence interval [CI], 27%-46%) in 2009 (pre-DAA era) to 2% (95% CI, 0%-4%) in 2021 (DAA era). Male sex, black race, and older age were associated with HCV viremia in 2009 but not in 2021. Injection drug use remained associated with HCV viremia in 2009 and 2021. Targeted interventions are needed to meet the HCV care needs of PWH who use drugs.

Keywords: HIV; elimination; health equity; hepatitis C.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. M. S. reports research funds paid to his institution by Janssen, Vir, and GSK (HBV); and consulting fees from AbbVie, Antios, Assembly Bio, Atea, GSK, Gilead, Precision Bio, and Vir. O. F. N. reports research funds paid to her institution by Abbvie, Inc; and consulting fees from Gilead. D. T. reports consulting fees from Merck, Excision Bio, and Evrys Bio. S. H. M. reports materials support from Abbott Diagnostics. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Estimated proportion of each study population (all people with HIV in care or subset who ever tested HCV antibody positive) who had HCV viremia each year in the cohort with pointwise 95% confidence intervals, 2009–2021. Abbreviations: HCV, hepatitis C virus; PWH, people with human immunodeficiency virus.
See this image and copyright information in PMC

References

    1. World Health Organization . Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030. Geneva, Switzerland; WHO, 2022.
    1. Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 2016; 16:797–808. - PubMed
    1. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054–8. - PubMed
    1. Braun DL, Hampel B, Ledergerber B, et al. A treatment-as-prevention trial to eliminate hepatitis C among men who have sex with men living with HIV in the Swiss HIV Cohort Study. Clin Infect Dis 2020; 73:e2194–202. - PubMed
    1. Martinello M, Yee J, Bartlett SR, et al. Moving towards hepatitis C microelimination among people living with human immunodeficiency virus in Australia: the CEASE study. Clin Infect Dis 2020; 71:1502–10. - PubMed

Publication types

Substances